|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,529 JPY | +0.72% |
|
-4.56% | -12.08% |
| 2023 | Mithra Pharmaceuticals' License Partner Files for Estelle's Marketing Approval in Japan; Shares Jump | MT |
| 2023 | Alvotech Partner Secures Marketing Approval for Stelara Biosimilar AVT04 in Japan | MT |
Fuji Pharma Co., Ltd. reported earnings results for the half year ended March 31, 2023. For the half year, the company reported sales was JPY 19,225 million. Net income was JPY 1,772 million.
Basic earnings per share from continuing operations was JPY 72.95.
| 1st Jan change | Capi. | |
|---|---|---|
| -12.08% | 236M | |
| +31.37% | 588B | |
| -2.60% | 364B | |
| +20.83% | 326B | |
| +5.69% | 285B | |
| +14.83% | 239B | |
| +9.93% | 210B | |
| -6.95% | 200B | |
| +10.77% | 167B | |
| +0.10% | 161B |
FUJI PHARMA CO., LTD. 